49 results
S-8
EX-5.1
BIAF
BioAffinity Technologies Inc
5 Jun 24
Registration of securities for employees
4:30pm
) the Plan. We have not performed any independent investigation other than the document examination described. We have assumed and relied
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
.
Patient enrollment is affected by many other factors, including:
the severity of the disease under investigation;
the patient eligibility criteria … related to the product, patient population, phase of investigation, trial sites, and investigators, and other aspects of a clinical trial
POS AM
7ri11 u3mjjf2t1n
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-1.1
ww08buqqaow7 dwh
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-4.2
5cgen1sxwxul 0p
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-4.1
k6gx q1kzpq
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
zohldlcxlhriyog6
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
whie4fs
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
39j10dc6z8d35fdsdoy
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-10.1
ikol1rrv 40
31 Jan 24
Departure of Directors or Certain Officers
4:05pm
424B5
rboq1evqkvqd8an1wu
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
w6w8qspg6f2eltsl
16 Nov 23
Shelf registration
5:23pm
S-3
EX-4.3
ri3ctu3ymb 0xcb
16 Nov 23
Shelf registration
5:23pm
S-8
EX-5.1
vo3erd tz6b
18 Oct 23
Registration of securities for employees
5:10pm